Lexeo Therapeutics, Inc.
As of Oct 22, 2026, Lexeo Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $2.89, 72.8% below its 52-week high and below its 200-day average, which is falling.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LXEO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LXEO among Biotechnology431st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …431 | LXEO | Stage 4 · wk 5 | 15 | −17.9% |
Lexeo Therapeutics: quick answers
What stage is Lexeo Therapeutics in?
As of Oct 22, 2026, Lexeo Therapeutics (LXEO) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean
Is Lexeo Therapeutics in an uptrend?
No. Lexeo Therapeutics is in a Stage 4 downtrend. It trades 46.4% below its 200-day average, which is falling.
How far is Lexeo Therapeutics from its 52-week high?
Lexeo Therapeutics closed at $2.89 on Oct 22, 2026, 72.8% below its 52-week high of $10.63. Its 52-week low is $2.63.
How has Lexeo Therapeutics performed over the past year?
As of Oct 22, 2026, Lexeo Therapeutics is down 69.9% over the past year and down 69.9% so far in 2026.
Which sector and industry is Lexeo Therapeutics in?
Lexeo Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.